Abstract:Question Does therapy with low-dose capecitabine maintenance after standard adjuvant chemotherapy reduce the risk of relapse and death in early-stage triple-negative breast cancer?Findings In this randomized clinical trial of 434 women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly higher 5-year disease-free survival (82.8% vs 73.0%; hazard ratio for risk of recurrence or death, 0.64).Meaning Among women with early-stage triple-negative breast cancer, maintenance therapy with low-dose capecitabine significantly improved disease-free survival at 5 years.Importance Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed.Objective To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer.Design, Setting, and Participants Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy.Interventions Eligible patients were randomized 1:1 to receive capecitabine (n = 222) at a dose of 650 mg/m2 twice a day by mouth for 1 year without interruption or to observation (n = 221) after completion of standard adjuvant chemotherapy.Main Outcomes and Measures The primary end point was disease-free survival. Secondary end points included distant disease-free survival, overall survival, locoregional recurrence-free survival, and adverse events.Results Among 443 women who were randomized, 434 were included in the full analysis set (mean [SD] age, 46 [9.9] years; T1/T2 stage, 93.1%; node-negative, 61.8%) (98.0% completed the trial). After a median follow-up of 61 months (interquartile range, 44-82), 94 events were observed, including 38 events (37 recurrences and 32 deaths) in the capecitabine group and 56 events (56 recurrences and 40 deaths) in the observation group. The estimated 5-year disease-free survival was 82.8% in the capecitabine group and 73.0% in the observation group (hazard ratio [HR] for risk of recurrence or death, 0.64 [95% CI, 0.42-0.95]; P = .03). In the capecitabine group vs the observation group, the estimated 5-year distant disease-free survival was 85.8% vs 75.8% (HR for risk of distant metastasis or death, 0.60 [95% CI, 0.38-0.92]; P = .02), the estimated 5-year overall survival was 85.5% vs 81.3% (HR for risk of death, 0.75 [95% CI, 0.47-1.19]; P = .22), and the estimated 5-year locoregional recurrence-free survival was 85.0% vs 80.8% (HR for risk of locoregional recurrence or death, 0.72 [95% CI, 0.46-1.13]; P = .15). The most common capecitabine-related adverse event was hand-foot syndrome (45.2%), with 7.7% of patients experiencing a grade 3 event.Conclusions and Relevance Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly improved 5-year disease-free survival.Trial Registration ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT01112826">NCT01112826</a>

Clinical Efficacy of Capecitabine Combined with Autologous Cytokine-induced Killer Cells Maintenance Therapy in Treatment of Metastatic Triple Negative Breast Cancer

Meta-Analysis Of Capecitabine-Based Chemotherapy Versus Capecitabine-Free Chemotherapy In Patients With Metastatic Breast Cancer

Capecitabine Maintenance Therapy for XT Chemotherapy-Sensitive Patients with Metastatic Triple-Negative Breast Cancer.

Clinical observation of capecitabine maintenance therapy after response to capecitabine -based combination chemotherapy in patients with metastatic breast cancer

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients.

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Curative Effect and Safety of Autologous Cytokine-induced Killer Cells Combined with Chemotherapy in the First Line Maintenance Treatment of Non-small Cell Lung Cancer

Capecitabine maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer

Clinical observation of maintenance therapy with autologous cytokine-induced killer cells in patients with medium and advanced non-small cell lung cancer after first-line treatment

Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial

Prospective Study of Cyclophosphamide, Thiotepa, Carboplatin Combined with Adoptive DC-CIK Followed by Metronomic Cyclophosphamide Therapy As Salvage Treatment for Triple Negative Metastatic Breast Cancers Patients (aged <45)

Hormone therapy (HT) or capecitabine (CAP) as maintenance therapy following the first-line chemotherapy in HR+/HER2-ABC/MBC: Secondary endpoint adverse effects (AEs) and toxicity report of OVERSTEP Trial (ZJCH15001/CBCSG 035).

Efficacy Comparison of Capecitabine Metronomic Chemotherapy and Conventional Chemotherapy in the Maintenance of Elderly Patients with Metastatic Breast Cancer

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214

Adjuvant Capecitabine with Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): an Open-Label, Randomized, Multicenter, Phase III Trial

Capecitabine-based chemotherapy for metastatic colorectal cancer

Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.

Clinical effectiveness and safety of gemcitabine plus capecitabine in the treatment of advanced triple-negative breast cancer